6 hours Ago By Defense World Staff
Investment analysts at BTIG Research assumed coverage on shares of Avalo Therapeutics ( NASDAQ:AVTX – Get Free Report ) in a report issued on Thursday, MarketBeat.com reports. The brokerage set a “buy” rating and a $40.
00 price target on the stock. BTIG Research’s target price suggests a potential upside of 348.93% from the company’s previous close.
Separately, HC Wainwright assumed coverage on Avalo Therapeutics in a research report on Thursday, October 24th. They set a “neutral” rating for the company. Read Our Latest Analysis on AVTX Avalo Therapeutics Stock Performance Institutional Inflows and Outflows Several institutional investors have recently added to or reduced their stakes in AVTX.
Affinity Asset Advisors LLC boosted its stake in shares of Avalo Therapeutics by 350.0% during the 2nd quarter. Affinity Asset Advisors LLC now owns 45,000 shares of the company’s stock worth $561,000 after purchasing an additional 35,000 shares during the last quarter.
Logos Global Management LP acquired a new stake in Avalo Therapeutics during the second quarter worth approximately $6,722,000. Ikarian Capital LLC grew its stake in Avalo Therapeutics by 1,673.0% in the 3rd quarter.
Ikarian Capital LLC now owns 970,359 shares of the company’s stock worth $9,218,000 after acquiring an additional 915,629 shares during the period. Finally, RA Capital Management L.P.
acquired a new position in Avalo Therapeutics in the 3rd quarter valued at $9,186,000. Institutional investors and hedge funds own 87.06% of the company’s stock.
About Avalo Therapeutics ( Get Free Report ) Avalo Therapeutics, Inc, a clinical stage biotechnology company, focuses on the development of therapies for the treatment of immune dysregulation in the Unites States. The company's drug candidates include AVTX-009, an Anti-IL-1ß monoclonal antibody which is under Phase I targeting inflammatory diseases; and AVTX-008, a fully human B and T lymphocyte attenuator agonist fusion protein for the treatment of immune dysregulation disorders. See Also Five stocks we like better than Avalo Therapeutics What Are Growth Stocks and Investing in Them Opal Fuels CEO on Steering the Future of Renewable Natural Gas What Do S&P 500 Stocks Tell Investors About the Market? MicroStrategy Joins Nasdaq-100: 2 Crypto Stocks Set to Win What Are Dividend Achievers? An Introduction 2 Underrated Quantum Computing Companies Starting to Rally Receive News & Ratings for Avalo Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Avalo Therapeutics and related companies with MarketBeat.
com's FREE daily email newsletter ..
